GSK
London, X0files as GSK plc
$602m in 13 US stocks at the end of 30 June 2026. The top 10 are 97.5% of the money. It changed about 8.3% of the portfolio this quarter.
Value
$602m
Stocks
13
Top 10 share
97.5%
Turnover
8.3%
What changed this quarter
New
Bought for the first time this quarter.
None this quarter.
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
None this quarter.
Sold out
Sold their entire stake.
None this quarter.
Holdings
- Biontech SEBNTX
- Share
- 13.7%
- Value
- $83m
- Shares
- 889,824
Held
- Bicycle TherapeuticsBCYC
- Share
- 1.1%
- Value
- $6m
- Shares
- 1,529,561
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| CRISPR Therapeutics AGCRSP | 29.2% | $176m | 3,220,627 | Held |
| Wave Life SciencesWVE | 17.6% | $106m | 18,245,691 | Held |
| Vir BiotechnologyVIR | 14.5% | $87m | 8,550,954 | Held |
| Biontech SEBNTX | 13.7% | $83m | 889,824 | Held |
| IDEAYA BiosciencesIDYA | 8.3% | $50m | 1,333,333 | Held |
| CytokineticsCYTK | 4.8% | $29m | 340,434 | Held |
| Lyell ImmunopharmaLYEL | 3.5% | $21m | 1,512,659 | Held |
| Spero TherapeuticsSPRO | 3.4% | $20m | 9,190,606 | Held |
| NkartaNKTX | 1.5% | $9m | 3,150,732 | Held |
| Fulcrum TherapeuticsFULC | 1.1% | $7m | 1,785,714 | Held |
| Bicycle TherapeuticsBCYC | 1.1% | $6m | 1,529,561 | Held |
| CVRxCVRX | 0.9% | $5m | 1,007,583 | Held |
| RegenxbioRGNX | 0.5% | $3m | 271,456 | Held |
Over time and by industry
Value over time
Dec '25
Jun '26
Value is down 24.6% since 31 December 2025.
Where the money is
Health care85.2%
Other14.8%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.